Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer

By rosaguerrero • July 20, 2022

Shin DS, Park K, Garon E, Dubinett S. Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer. Semin Oncol. 2022 Jul 2:S0093-7754(22)00045-8. doi: 10.1053/j.seminoncol.2022.06.005. Epub ahead of print. PMID: 35851153.

Tags: EZH2, Hematology/Oncology, immunotherapy, Lung cancer, PD-1 blockade, PRC2, Pulmonary, Critical Care & Sleep Medicine, Veterans Administration

irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets

Bejan CA, Wang M, Venkateswaran S, Bergmann EA, Hiles L, Xu Y, Chandler GS, Brondfield S, Silverstein J, Wright F, de Dios K, Kim DM,[...]

Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test

Zeng W, Liu CC, Li S, Zhou Y, Stackpole ML, Xiao Y, Hu R, Tang C, Liu Q, Zeng W, Yeh A, Melehy A, Tran[...]

Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to delineate characteristics of this site of recurrence

López JCV, Ho A, Hughes KS, Bardia A, Vidula N. Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to[...]